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To discover quantitative trait loci for intraocular pressure, a major risk factor for glaucoma and the only modifi-
ableone,weperformedagenome-wideassociationstudyonadiscoverycohort of2175 individuals fromSydney,
Australia. We found a novel association between intraocular pressure and a common variant at 7p21 near to
GLCCI1 and ICA1. The findings in this region were confirmed through two UK replication cohorts totalling
4866 individuals (rs59072263, Pcombined 5 1.10 3 10
28). A copy of the G allele at this SNP is associated with an
increase in mean IOP of 0.45 mmHg (95%CI 5 0.30–0.61 mmHg). These results lend support to the implication
of vesicle trafficking and glucocorticoid inducibility pathways in the determination of intraocular pressure
and in the pathogenesis of primary open-angle glaucoma.
INTRODUCTION
Elevated intraocular pressure (IOP) is a major risk factor for the
development and progression of glaucoma, which is the com-
monest cause of irreversible blindness worldwide (1). Globally,
60 million people are affected of whom 8.4 million are blind in
both eyes (2). Before this end stage there is a greater risk of
falls (3), fractures (4) and motor vehicle collisions (5).
The link between high IOP and glaucoma is clearly seen when
there is a readily identifiable cause for raised IOP such as trauma,
inflammation, dysgenesis or obstruction of the aqueous humour
drainage system in the trabecular meshwork of the iridocorneal
angle by iris tissue, pigment or other deposits (2). It is also
evident even when there is no clear cause or obstruction of the
iridocorneal angle. Glaucoma occurring under these latter condi-
tions is known as primary open-angle glaucoma (POAG) and is
the most prevalent form of glaucoma, causing the greatest
burden of disease (6). The risk of developing POAG is approxi-
mately five times higher in subjects with IOPs above the popula-
tion 95th centile than in subjects with lower IOPs (7); the higher
the IOP at screening, the greater the risk of POAG (8). Both mean
and maximum IOP have been reported as closely associated with
visual field deterioration (8–15) and optic nerve damage (16). In
a group of subjects affected by POAG despite untreated IOPs
below the population 95th centile (‘normal pressure’ glaucoma),
worse visual field damage was found in the eye with the higher
IOP (17). Furthermore, IOP is currently the only modifiable risk
factor for POAG. Therapeutic lowering of intraocular pressure
reduces the risk of developing glaucoma (18) and retards disease
progression (19–21). In addition to inherent interest, and its role
asamodifiable trait on thecausalpath todisease, theknownhetero-
geneity of POAG means that a focus on the genetic basis of IOP
may be more powerful than studies of POAG directly (22,23).
Heritability estimates for adult IOP range from 0.29 to 0.62
(24–28). To date, two regions have been reported to be robustly
associated with IOP as a result of linkage analyses, one at 10q22
from a Tasmanian glaucoma pedigree (29) and one at 5q22 in a
West African cohort (30). A recent Dutch genome-wide associ-
ation study (GWAS) for IOP (31) also found two associated
loci, one of which (TMCO1) overlaps with a previously published
POAG GWAS locus (32).
Further elucidation of the genetic basis of IOP would aid in
understanding the biology of a major blinding disease (POAG),
in risk stratification for development and progression of the
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disease and in providing therapeutic targets. In order to identify
genomic variants that contribute to the determination of IOP,
we performed a GWAS as a component of the Wellcome Trust
Case Control Consortium 2 (WTCCC2) (http://www.wtccc.org.
uk/ccc2/).
RESULTS
A total of 2765 discovery samples from the Blue Mountains Eye
Study (BMES) were genotyped on the Illumina 660W-Quad
array at the Wellcome Trust Sanger Institute (WTSI). Genotype
imputation was performed in all 2302 individuals passing geno-
type quality control (QC) using IMPUTE2 (33) and the 1000
Genomes reference panel (34) (see Materials and Methods and
Supplementary material online). SNPs with low imputation
quality (info , 0.7) (35) were excluded, resulting in 6 235 970
SNPs on chromosomes 1–22 which passed QC.
For each individual, the mean IOP between their two eyes was
calculated. If an individual had undergone surgery or treatment
to an eye, data from that eye were excluded. If the difference
in IOP between an individual’s two eyes was .10 mmHg, the
individual was excluded. Eight outlying individuals whose mea-
surements did not conform to a normal distribution were also
removed (see Materials and Methods). After genotype and
phenotype QC, a total of 2175 samples were available for
analysis.
A linear regression fitting an additive model was performed in
SNPTEST (https://mathgen.stats.ox.ac.uk/genetics_software/
snptest/snptest.html), where genotype, accounting for imput-
ation uncertainty, was set as the explanatory variable and
mean IOP as the response variable (Fig. 1). Age and sex were
included as continuous and categorical covariates, respectively.
This analysis will be referred to as the primary scan. The
genomic inflation statistic (l) was 1.01 (Supplementary Mater-
ial, Fig. S1), suggesting that population structure was not a
major problem in our discovery analyses.
Replication of the primary scan was attempted at 31 SNPs
covering 17 regions (Supplementary Material online, Table S1
and see Materials and Methods), of which two were regions pre-
viously found to be associated with IOP (31). Two platforms
were used for the first phase of replication; genotypes for four
SNPs were taken from the custom built Immunochip (36) (see
Materials and Methods), and genotypes for the other 27 SNPs
were obtained from a Sequenom plex. Results from discovery
and replication were combined using a fixed effects
meta-analysis by averaging the estimated effect size parameter
across the data sets, weighting by the inverse of the variance in
the estimates.
For the first phase of replication, we used individuals from the
European Prospective Investigation into Cancer (EPIC) Norfolk
cohort (see Materials and Methods). Following QC, data were
available for 2833 individuals genotyped on Sequenom and
2493 individuals genotyped on Immunochip (all with age, sex
and mean IOP data) with 2461 individuals overlapping
between the Sequenom and Immunochip replication cohorts.
The results from our data at SNPs previously found to be asso-
ciated with glaucoma (32,37–39) or IOP (31) are shown in
Table 1. Notably, the discovery data in our study contributed to
the replication phase in the IOP GWAS (31). An SNP in
TMCO1 (rs7555523), which has been associated with IOP (31)
showed evidence for association with mean IOP in both our dis-
covery (P ¼ 0.0303) and replication data (P ¼ 1.70 × 1023).
At the other region previously associated with IOP (31), on
chromosome 17p13 (rs11656696), there was no evidence for as-
sociation in our discovery data (P ¼ 0.548), whereas there was
evidence for association in our replication data (P ¼ 0.016).
One of the SNPs previously associated with POAG (39)
was also associated with mean IOP in our data, (rs4236601,
P ¼ 1.46 × 1023). The remaining previously associated SNPs
were not associated (P , 0.1) with IOP in our discovery data.
Following first phase replication, one of the newly identified
regions reached a Pcombined ,5 × 1028. This was on chromo-
some 7p21 and the top SNP (rs59072263, Pcombined ¼ 2.32 ×
1028) is between the genes ICA1 and GLCCI1 (Fig. 2 and Sup-
plementary Material, Fig. S2). Genotypes at this SNP were
imputed in the discovery data and directly genotyped in the rep-
lication. To check the reliability of the imputed calls, a subset of
214 discovery samples were directly genotyped at rs59072263.
The concordance between the imputed and genotyped calls
was 0.96 (eight out of 214 discordant calls) and the correlation
was 0.87, suggesting the imputation at this locus is acceptable.
No evidence for replication at P , 0.05 was found at the other
14 regions (Supplementary Material, Table S1). Two SNPs at
11p12 (rs10430986 and rs12222492) showed suggestive evi-
dence for association in the same direction as the discovery
data (P ¼ 0.07, P ¼ 0.11), although data were not available
Figure 1. Plot of genome-wide association results after fitting the additive model in SNPTEST. Genome-wide association results in the discovery data at 6 235 970
SNPs (5 718 276 imputed, 517 694 genotyped), each represented as a point on the plot. Chromosomes are coloured dark blue and light blue alternatively, as labelled on
the X-axis. The –log10 (P-value) is shown on the Y-axis. The locus identified in this study as being associated with intraocular pressure is highlighted in red and
labelled by chromosomal region.
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for the top SNP in the region (11-41102934). This locus may be
worth additional investigation.
A second round of replication of the 7p21 association was next
attempted in 2033 individuals from TwinsUK (40), in which the
genotypes at rs59072263 were imputed. The SNP had a one-
sided P-value of 0.053 assuming the same risk allele as the dis-
covery, giving combined evidence across the three cohorts of
P ¼ 1.10 × 1028 (Supplementary Material, Fig. S3), where
the G allele is associated with an IOP increase of 0.45 mmHg
(95% CI ¼ 0.30–0.61 mmHg).
Replication of the signal of association at 7p21 was also
assessed in the large Dutch meta-analysis (31) of IOP comprising
9680 individuals of European ancestry. The associated SNP
rs59072263 was not genotyped in this study, but the best avail-
able tag (rs6959703; genotype correlation, r2 ¼ 0.61) showed
a one-sided P-value ¼ 0.017. Imputation of genotypes by the
Rotterdam group at rs59072263, using MACH (http://www.sp
h.umich.edu/csg/abecasis/MACH/index.html) and the 1000
Genomes data, was also attempted but showed weaker evidence
of association (one-sided P-value ¼ 0.178), However, unlike
the discovery data and TwinsUK data, which had imputation ac-
curacy (‘IMPUTE info’ and ‘MACH r2’, respectively) of 0.95
and 0.89 at rs59072263, the largest component of the Dutch
meta-analysis, comprising almost two-thirds of the study, had
MACH r2 , 0.75. Therefore, particularly in light of the clear
replication at the best genotyped tag SNP, the lack of replication
in the imputed data at P , 0.05 may be due in part to the loss of
statistical power which results from the increased noise (imput-
ation uncertainty) in the inferred genotypes (41). We note that
the risk allele is the same in all three replication cohorts.
We also undertook a pathway analysis of SNPs with P , 1024
(see Materials and Methods), but this failed to pinpoint any path-
ways with a compelling biological connection to IOP biology.
DISCUSSION
We have thus identified a novel association between a region on
chromosome 7p21 and mean IOP. Since IOP is on the causal
pathway to glaucoma, this association is also relevant for suscep-
tibility to glaucoma. The most associated SNP in this region is
flanked by two genes, ICA1 and GLCCI1, both of which have
been shown to be expressed in the human eye (information
from the EMBL-EBI website, see http://www.ebi.ac.uk/gxa/).
ICA1 encodes a protein involved in the regulation of secretory
vesicle trafficking (42) and has been implicated as an auto-antigen
in insulin-dependent diabetes mellitus (43) and primary Sjögren’s
syndrome (44). Vesicular metabolism pathways have previously
been ascribed a role in the pathobiology of POAG: a case–
control GWAS of POAG found associations with the CAV1 and
CAV2 genes which control vesicle transport in transcytosis
mechanisms (39). The latter mediate drainage of aqueous
humour from the eye and it is recognized that increased IOP
Table 1. Evidence for association in the discovery data at SNPs previously found to be associated with glaucoma or IOP







1 rs4656461 163953829 TMCO1 G 0.309 (G) — Glaucoma (32)
1 rs7555523 163985603 TMCO1 C 0.030 (C) 1.70 × 1023 (C) IOP (31)
2 rs3213787 45500328 SRBD1 A 0.130 (A) — Glaucoma (37)
6 rs735860 53231077 ELOVL5 C 0.796 (T) — Glaucoma (37)
7 rs4236601 115949965 CAV1, CAV2 A 1.46 × 1023 (A) — Glaucoma
(POAG)
(39)
9 rs4977756 22058652 CDKN2B-AS1 A 0.623 (A) 0.590 (A) Glaucoma (32)
15 rs3825942 72006635 LOXL1 G 0.553 (A) — Glaucoma
(exfoliation)
(38)
17 rs11656696 9974404 GAS7 G 0.548 (G) 0.016 (G) IOP (31)
‘—’ data not available.
Figure 2. Regional association plot of the locus found to be associated with
intraocular pressure. The –log10(P-values) for the additive model SNP associ-
ation in SNPTEST are shown on the upper part of the plot. SNPs are coloured
based on their r2 with the labelled SNP, r2 calculated in the 1958 Birth Cohort
data. Circles represent directly genotyped SNPs, and triangles represent
imputed SNPs. The bottom part of the plot shows the fine scale recombination
rate estimated from individuals in the HapMap panel, with genes marked by hori-
zontal blue lines.
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results from a failure of drainage rather than an overproduction
of aqueous humour.
The GLCCI1 gene has been ascribed a role in the sensitivity of
various tissues to glucocorticoids, initially thymoma cell lines
(45) and recently in the degree of response to glucocorticoid
therapy in asthma (46). The variant associated with glucocortic-
oid therapy in asthma (46) was not associated with IOP in our dis-
covery (P ¼ 0.8), and was not in strong linkage disequilibrium
(LD) with the IOP associated variant we identified (r2 ¼ 0.114
in the 1000 Genomes data). Topical glucocorticoid therapy
causes raised IOP in susceptible individuals (47) and the likeli-
hood of such an IOP response is greater in POAG patients,
POAG suspects and first-degree relatives of POAG patients
(48). The BMES has previously reported an association
between use of inhaled corticosteroids and a finding of elevated
IOP or glaucoma in subjects with a glaucoma family history (49).
Furthermore, patients with POAG have elevated blood (50–54)
and aqueous humour (52) levels of the endogenous glucocortic-
oid cortisol compared with age-matched normal subjects. The
first glaucoma gene identified, MYOC (55), was a glaucoma can-
didate gene because of its glucocorticoid inducibility (56). It is
thus plausible that GLCCI1 may influence IOP via the response
to endogenous cortisol.
The effect size of the novel associated SNP we report (Table 2)
is substantially higher than that of previously reported SNPs for
IOP (beta ¼ 0.45 for rs59072263 when compared with 0.19 for
rs11656696 and 0.28 for rs7555523). We can get some indica-
tion of the possible consequences of the SNP on POAG, based
on its measured effect for IOP, from population studies which
relate changes in IOP to POAG risk. This approach suggests
that each copy of the G allele at rs59072263 gives an expected
odds ratio for POAG of 1.08 (57) and, in untreated glaucoma
(in our discovery cohort, in common with other cohorts from
the developed world, over 50% of glaucoma was undiagnosed
at initial ascertainment) (58), each copy of the allele gives an
extra 6% likelihood of significant deterioration in vision (59).
The novel associated SNP has a higher risk allele frequency
(RAF) than previously reported SNPs (RAF ¼ 0.88 for
rs59072263 when compared with 0.58 for rs11656696 and
0.12 for rs7555523) so a higher proportion of our cohort will
carry at least one potentially deleterious allele.
In summary, we have performed a GWAS which has newly
identified a region at 7p21 associated with IOP; the region is
between the ICA1 and GLCCI1 genes, both of which may plaus-
ibly be invoked in the determination of IOP.
MATERIALS AND METHODS
Ethics statement
The Blue Mountains Eye Study received ethical approval by the
Western Sydney Area Health Service Human Ethics Committee
in 1991. Written, informed consent was obtained from all parti-
cipants. The EPIC-Norfolk study received approval from the
East Norfolk and Waveney Research Governance Committee
on 08/03/06 and from the Norfolk1 Research Ethics Committee
on 06/02/06.
Discovery samples
The IOP data from the discovery cohort were gathered as part of
the Blue Mountains Eye Study (BMES), a survey of vision and
common eye diseases in the Blue Mountains region west of
Sydney, Australia. The study was approved by the Western
Sydney Area Health Service Human Ethics Committee.
Written, informed consent was obtained from all participants.
The population has been described in detail in a previous
report (60). To summarize, a door-to-door census of the study
region was carried out based on maps from the Australian
Bureau of Statistics. All permanent non-institutionalized resi-
dents with birthdates before January 1, 1943 were invited to
attend for eye examination. Of the 4433 eligible individuals,
3654 (82.4%) were examined. If the 278 individuals who had
died or moved away from the area are excluded, this translates
to an 87.9% response rate, which compares well with most
population-based research in glaucoma (61–63). Subjects
attending the examination underwent IOP measurement by
applanation tonometry using a Goldmann applanation tonom-
eter (Haag-Streit, Bern, Switzerland). Goldmann applanation
tonometry is the international standard for accurate determin-
ation of IOP in ophthalmic clinical practice. Tonometry could
not be performed in 12 subjects (0.3%). In a further nine uniocu-
lar subjects, IOP could only be measured unilaterally, in such
cases, the value for that single eye was used. Data from subjects
receiving past or present treatment designed to lower IOP were
excluded from the analysis.
Replication samples
The European Prospective Investigation into Cancer (EPIC) was
conceived as a pan-European study of the genetic and environ-
mental determinants of cancer (64). The EPIC-Norfolk cohort
Table 2. Evidence for association with mean IOP at the 7q21 locus
Chr Position rsID Risk allele RAF Discovery (BMES) Replication (EPIC) Replication (TWINSUK) Meta
P-value P-value P-value P-value
Beta Beta Beta Beta
SE SE SE SE
7p21 8118592 rs59072263 G 0.88 9.02 × 1026 4.01 × 1024 0.106 1.10 × 1028
0.61 0.42 0.28 0.45
0.136 0.12 0.17 0.08
RAF, risk allele frequency.
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comprised 25 000 men and women aged 40–79 recruited
between 1993 and 1997 and was predominantly white, with a
mixture of urban–rural residence, socioeconomic standards
and educational achievements reflecting the population of the
county of Norfolk. From the outset, data collection was
expanded to include extensive lifestyle and biological data to
enable a broader longitudinal study of the determinants of
health and disease (65). A third health examination was initiated
in 2006 with the purpose of assessing objectively various phys-
ical, cognitive and ocular characteristics of participants now
aged 48–91 years. The third health examination was reviewed
and approved by the East Norfolk and Waverney NHS Research
Governance Committee (2005EC07L) and the Norfolk Research
Ethics Committee (05/Q0101/191). The work was performed in
accordance with the principles of the Declaration of Helsinki.
IOP was measured three times in each eye using a noncontact
Ocular Response Analyser (ORA, Reichert Inc., Buffalo, NY,
USA) to generate the Goldmann Correlated IOP (IOPg) which
the manufacturers have calibrated with Goldmann applanation
tonometry. Data from subjects receiving past or present treat-
ment designed to lower IOP were excluded from the analysis.
The TwinsUK data were obtained from a panel of individuals
who were recruited from the UK Adult Twin Registry (40) based
at St Thomas’ Hospital, London. The subjects were twin volun-
teers from the general population. Subjects were recruited for
studies other than eye studies, and subsequently asked to
attend for an eye examination. All subjects provided informed
consent, and the study was reviewed by the Local Research
Ethics Committee. The methods adopted in this study adhered
to the tenets of the Declaration of Helsinki Principles. IOP meas-
urement was performed with the Goldmann applanation tonom-
eter and the ORA (IOPg). Data from subjects receiving past or
present treatment designed to lower IOP were excluded from
the analysis.
DNA preparation
DNA was extracted from whole blood. Quality was validated
using the Sequenom iPLEX assay designed to genotype four
gender SNPs and 26 SNPs present on the Illumina Beadchips.
DNA concentrations were quantified using a PicoGreen assay
(Invitrogen) and an aliquot assayed by agarose gel electrophor-
esis. A DNA sample was considered to pass quality control if the
DNA concentration was ≥50 ng/ml, the DNA was not degraded,
the gender assignment from the iPLEX assay matched that pro-
vided in the patient data manifest and genotypes were obtained
for at least two-thirds of the SNPs on the iPLEX.
Genotyping
Discovery samples were genotyped at the Sanger Institute on
the Illumina Infinium platform using the Human660W-Quad,
a custom chip designed by WTCCC2 and comprising
Human550 supplemented with 60 000 additional probes that
were intended to allow the genotyping of common CNVs from
the Structural Variation Consortium (66). Replication genotyp-
ing for the UK EPIC cohort was carried out at the Sanger Institute
using the Illumina Immunochip, a custom chip designed by the
Immunochip Consortium and WTCCC2, comprising 196 524
SNPs. For both chips, bead-intensity data were processed and
normalized for each sample in BeadStudio; data for successfully
genotyped samples were extracted and genotypes called using
Illuminus. Replication genotyping on the Sequenom plex was
also carried out at the Sanger Institute. Imputation was per-
formed with reference to HapMap release 22 CEU by using
IMPUTE2 (33). Genotyping for the TwinsUK cohort was
carried out by using Illumina (San Diego, CA, USA) genotyping
platforms; the Human Hap 300k Duo and Human Hap610 Quad
array. All SNPs passed quality control criteria (Hardy–Wein-
berg equilibrium P . 0.001, minor allele frequency of at least
0.04, genotyping success rate for the SNP at least 95%). Imput-
ation was performed with reference to the 1000 Genomes panel
using minimac (http://genome.sph.umich.edu/wiki/Minimac)
and association analysis was performed using mach2qtl.
Quality control
SNPs were excluded if the Fisher information for the allele fre-
quency was not close to unity (information ,0.98) or if the
minor allele frequency (MAF) was very low (defined as
,0.01%), or for extreme departures from Hardy–Weinberg
equilibrium (HWE P-value ,10220). Full details of the quality
control methods employed in the Wellcome Trust Case Control
Consortium 2 (WTCCC2) have been published elsewhere (67).
Also see Supplementary material online, SNP Imputation.
For quality control of samples, a Bayesian clustering method
was used to infer and exclude outlying individuals on the basis of
ancestry, call rate, heterozygosity and signal intensity (67). To
remove signal intensity outliers observed for raw intensity
data, the difference between the A channel intensity and the B
channel intensity was averaged over all SNPs on autosomes
for each sample. A similar approach was used taking intensity
measures from the A channel on the non-pseudo autosomal X
chromosomes to identify outliers and infer gender. Samples
were removed if their inferred gender was discordant with the
recorded gender after cross-checking with original database
entries, or if ,90% of the SNPs typed by Sequenom on entry
to sample handling (discussed earlier) agreed with the genome-
wide data. To obtain a set of putatively unrelated individuals, we
estimated genome-wide identity by descent (IBD) given identity
by state (IBS) for all pairs of individuals using a Hidden Markov
Model. One of each pair of related individuals where zero alleles
shared IBD (IBD0) was ,95% was removed in the initial asso-
ciation analysis, excluding the member of the pair with the
lowest call rate. Where unexpected duplicates were identified,
both of the identical samples were removed to avoid incorrect
phenotype assignment. Ancestry outliers were removed by pro-
jecting the WTCCC2 individuals on to the first two principal
components of a PCA of the CEU, YRI and JPT/CHB
HapMap individuals. Samples were excluded based on evidence
of non-European ancestry.
A total of 463 individuals were excluded from the discovery
cohort following these initial quality control checks.
1000 Genomes imputation
We used 120 CEU phased haplotypes from the 1000 Genomes
project (34) June 2010 release for the haploid reference panel.
After imputation, a total of 7 642 395 SNPs were available for
analysis, of which 712 4701 were imputed. SNPs were filtered
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using an information threshold of 0.7, an allele frequency thresh-
old of 0.1% and Hardy–Weinberg filter of P , 10220 giving a
final total of 6 235 970 SNPs for analysis (5 718 276 imputed,
517 694 genotyped).
Pathway analysis
We undertook a pathway analysis using the approach reported
previously in Sawcer et al. (68). Briefly, we took all SNPs with
P , 1024 in the discovery data and we used these to define asso-
ciation regions (with at least one such SNP) and compiled a list of
all genes in these regions. This list is matched to the Gene Ontol-
ogy (GO) pathway database. A Fisher’s exact test is used to give
a P-value for each pathway.
There were 513 genes in our associated regions of which 394
were in the GO database. The Fisher’s exact test highlighted 10
pathways with P , 1024 namely: anchored to membrane;
monooxygenase activity; N,N-dimethylaniline monooxygenase
activity; glucuronosyltransferase activity; alkaline phosphatase
activity; phospholipid scramblase activity; xenobiotic metabolic
process; response to xenobiotic stimulus; cellular response to
xenobiotic stimulus; phospholipid scrambling.
Of the pathways identified, those of potentially most interest
from a mechanistic viewpoint are ‘phospholipid scramblase ac-
tivity’ and ‘phospholipid scrambling’. This metabolic activity is
a key part of lipid translocation, which drives endo- and exocyt-
osis of microvesicles (69,70). It is thus plausible that this meta-
bolic activity is important in the transcytotic movement of
aqueous humour across the trabecular meshwork which is a
key determinant of IOP as already mentioned in the manuscript.
We also implemented a number of slight variations on this
analysis as in Sawcer et al. (68), for example, only including
the nearest gene to an associated SNP. These alternative analyses
also failed to pinpoint any pathways with a natural biological
connection to IOP biology.
Phenotype
Mean IOP was regressed against age and sex and all eight
samples with residuals .10 were removed from the primary ana-
lysis. From the replication analysis, 21 individuals with residuals
.10 were removed. In the primary analysis, these phenotype
outliers were excluded because they can lead to false positive
associations. In order to check that we were not missing any
true associations by excluding outliers, the analysis was repeated
with inclusion of the phenotypic outliers, and a small number of
regions (4) were chosen for replication based on this scan. One
region for replication was also taken from the analysis fitting a
general model with residual outliers included.
Regions were shortlisted for replication if they had at least one
SNP with P , 1025 in the primary scan, or P , 1025 in the scan
including the eight residual outliers and P , 1024 in the primary
scan. Where possible, the SNP with the smallest P-value in each
region was replicated, along with the second best hit.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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